• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Certara launches SIVA Toolkit 2.0 for in vitro analysis

Certara launches SIVA Toolkit 2.0 for in vitro analysis

April 13, 2016
CenterWatch Staff

Certara, a global biosimulation technology-enabled drug development company, has launched the Simcyp In Vitro (Data) Analysis (SIVA) Toolkit 2.0 to assist drug development researchers with the analysis of complex in vitro studies. These studies are used to assess candidate drugs’ metabolism, transport and formulation properties.

“Global regulatory agencies are increasingly expecting sponsors to have a strong mechanistic understanding of drug metabolism, transport, and solubility/dissolution,” said Steve Toon, BPharm, Ph.D., president of Simcyp. “And the broader scientific community, including The International Transporter Consortium, which contains members of the FDA, are advocating the use of model-based approaches to maximize the value of data arising out of in vitro ADME studies. The SIVA Toolkit supports these types of data analyses which also in turn maximize the Simcyp Population-based Simulator’s predictive capabilities.”

The most valuable biosimulation models have two things in common—they are built using the most appropriate and highest quality data. The SIVA Toolkit provides better, richer and more relevant data from in vitro ADME experiments.

For example, permeability/transport assays measure how drugs move through the body, pass through cells, use transporters, get metabolized or a combination of all of them. While conventional in vitro analysis provides a single, global permeability value, the SIVA Toolkit generates parameters describing each of those physiological processes. SIVA’s approach ensures that researchers don’t lose any of that valuable information, which makes the resulting PBPK models more complete, powerful and relevant.

A standalone product, the SIVA Toolkit also allows researchers to optimize their in vitro ADME experiments, reducing the number of experiments and thus saving both time and money. It also gives sponsors more confidence to make important clinical trial decisions, such as determining whether they need to conduct certain studies.

It is a very user-friendly solution which features a predefined library of models for assessing drug metabolism, inhibition, transport and pharmaceutical formulation.

The SIVA Toolkit 2.0 now offers models for enzyme inhibition, allowing researchers to predict drug-drug interactions more accurately. It also includes Pharmaceutics-USP IV, Serial Dilution, Transfer and Two Phase Dissolution models.

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing